BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chu J, Gao F, Yan M, Zhao S, Yan Z, Shi B, Liu Y. Natural killer cells: a promising immunotherapy for cancer. J Transl Med 2022;20:240. [PMID: 35606854 DOI: 10.1186/s12967-022-03437-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Parsonidis P, Mamagkaki A, Papasotiriou I. CTLs, NK cells and NK-derived EVs against breast cancer. Hum Immunol 2023:S0198-8859(23)00042-3. [PMID: 36925436 DOI: 10.1016/j.humimm.2023.03.001] [Reference Citation Analysis]
2 Goff J, Hina M, Malik N, Mclardy H, Reilly F, Robertson M, Ruddy L, Willox F, Forget P. Can Opioid-Free Anaesthesia Be Personalised? A Narrative Review. JPM 2023;13:500. [DOI: 10.3390/jpm13030500] [Reference Citation Analysis]
3 Wong DCP, Ding JL. The mechanobiology of NK cells- 'Forcing NK to Sense' target cells. Biochim Biophys Acta Rev Cancer 2023;1878:188860. [PMID: 36791921 DOI: 10.1016/j.bbcan.2023.188860] [Reference Citation Analysis]
4 Slavin S. Immunotherapy with cure potential of multi-drug resistant hematologic malignancies using IL-2 preactivated intentionally mismatched donor lymphocytes.. [DOI: 10.21203/rs.3.rs-2606832/v1] [Reference Citation Analysis]
5 Zhai W, Chen S, Duan F, Wang J, Zhao Z, Lin Y, Rao B, Wang Y, Zheng L, Long H. Risk stratification and prognosis prediction based on inflammation-related gene signature in lung squamous carcinoma. Cancer Med 2023;12:4968-80. [PMID: 36056909 DOI: 10.1002/cam4.5190] [Reference Citation Analysis]
6 Sohn H, Cooper MA. Metabolic regulation of NK cell function: implications for immunotherapy. Immunometabolism (Cobham) 2023;5:e00020. [PMID: 36710923 DOI: 10.1097/IN9.0000000000000020] [Reference Citation Analysis]
7 Shah DD, Dave BP, Patel PA, Chorawala MR, Patel VN, Shah PA, Patel MP. Revamping the innate or innate-like immune cell-based therapy for hepatocellular carcinoma: new mechanistic insights and advanced opportunities. Med Oncol 2023;40:84. [PMID: 36680649 DOI: 10.1007/s12032-023-01948-4] [Reference Citation Analysis]
8 Cho SY, Jeong SM, Jeon YJ, Yang SJ, Hwang JE, Yoo BM, Kim HS. WT1 Pulsed Human CD141+ Dendritic Cell Vaccine Has High Potential in Solid Tumor-Targeted Immunotherapy. Int J Mol Sci 2023;24:1501. [PMID: 36675017 DOI: 10.3390/ijms24021501] [Reference Citation Analysis]
9 Xie N, Shen G, Gao W, Huang Z, Huang C, Fu L. Neoantigens: promising targets for cancer therapy. Signal Transduct Target Ther 2023;8:9. [PMID: 36604431 DOI: 10.1038/s41392-022-01270-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Fang C, Luo R, Zhang Y, Wang J, Feng K, Liu S, Chen C, Yao R, Shi H, Zhong C. Hepatectomy versus transcatheter arterial chemoembolization for resectable BCLC stage A/B hepatocellular carcinoma beyond Milan criteria: A randomized clinical trial. Front Oncol 2023;13:1101162. [PMID: 36923427 DOI: 10.3389/fonc.2023.1101162] [Reference Citation Analysis]
11 Wang X, Yang X, Wang Y, Chen Y, Yang Y, Shang S, Wang W, Wang Y. Combination of Expanded Allogeneic NK Cells and T Cell-Based Immunotherapy Exert Enhanced Antitumor Effects. Cancers (Basel) 2022;15. [PMID: 36612246 DOI: 10.3390/cancers15010251] [Reference Citation Analysis]
12 Kumar V, Bauer C, Stewart JH. Chasing Uterine Cancer with NK Cell-Based Immunotherapies. Future Pharmacology 2022;2:642-659. [DOI: 10.3390/futurepharmacol2040039] [Reference Citation Analysis]
13 Zhang W, Liu T, Jiang L, Chen J, Li Q, Wang J. Immunogenic cell death-related gene landscape predicts the overall survival and immune infiltration status of ovarian cancer. Front Genet 2022;13. [DOI: 10.3389/fgene.2022.1001239] [Reference Citation Analysis]
14 Wang X, Yang X, Yuan X, Wang W, Wang Y. Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential. Exp Hematol Oncol 2022;11:85. [PMID: 36324149 DOI: 10.1186/s40164-022-00341-7] [Reference Citation Analysis]
15 Porrata LF. Natural Killer Cells Are Key Host Immune Effector Cells Affecting Survival in Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation. Cells 2022;11:3469. [DOI: 10.3390/cells11213469] [Reference Citation Analysis]
16 Mushtaq MU, Shahzad M, Shah AY, Chaudhary SG, Zafar MU, Anwar I, Neupane K, Khalid A, Ahmed N, Bansal R, Balusu R, Singh AK, Abhyankar SH, Callander NS, Hematti P, Mcguirk JP. Impact of natural killer cells on outcomes after allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis. Front Immunol 2022;13:1005031. [DOI: 10.3389/fimmu.2022.1005031] [Reference Citation Analysis]
17 Zhang J, Chen P, Miao L. A bibliometric and scientific knowledge-map study of the chimeric antigen receptor (CAR) natural killer (NK) cell-related research from 2010 to 2022. Front Immunol 2022;13:969196. [DOI: 10.3389/fimmu.2022.969196] [Reference Citation Analysis]